Abstract
Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Current Gene Therapy
Title: Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy
Volume: 8 Issue: 3
Author(s): Akihiro Nawa, ChenHong Luo, Lumin Zhang, Yoko Ushjima, Daisuke Ishida, Maki Kamakura, Yasushi Fujimoto, Fumi Goshima, Fumitaka Kikkawa and Yukihiro Nishiyama
Affiliation:
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Abstract: Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Export Options
About this article
Cite this article as:
Nawa Akihiro, Luo ChenHong, Zhang Lumin, Ushjima Yoko, Ishida Daisuke, Kamakura Maki, Fujimoto Yasushi, Goshima Fumi, Kikkawa Fumitaka and Nishiyama Yukihiro, Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746422
DOI https://dx.doi.org/10.2174/156652308784746422 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Cytotoxicity of Novel Coumarin-1,2,3-triazole-1,2,4- Oxadiazole Hybrids as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Identifying and Validating Oncology Therapeutic Targets in the Post- Genomics Era
Current Genomics Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Current Designs and Developments of Fucoidan-based Formulations for Cancer Therapy
Current Drug Metabolism ADAM10 as a Target for Anti-Cancer Therapy
Current Pharmaceutical Biotechnology Unravelling the Antioxidant Potential, Alpha-Glucosidase Inhibitory Activity and Phenolic Composition of Dendrocalamus strictus Plantations Generated Biomass Waste (Leaves)
The Natural Products Journal Search for New and Novel Chemotherapeutics for the Treatment of Human Malignancies
Mini-Reviews in Medicinal Chemistry Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Quantification of Glycyrrhetic Acid in Human Plasma by LC–MS/MS: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Current Advances in Food Science & Health Promotion (Part I)
Current Pharmaceutical Biotechnology The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Application of Three-dimensional (3D) Tumor Cell Culture Systems and Mechanism of Drug Resistance
Current Pharmaceutical Design Pyrimidinone Associated Triazole Carboxamides: Synthesis, Characterization, Cytotoxicity and DNA Binding Studies
Current Bioactive Compounds Fe3O4 Nanoparticles Mediated Synthesis of Novel Isatin-dihydropyrimidinone Hybrid Molecules as Antioxidant and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry